<DOC>
	<DOCNO>NCT00078988</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , thiotepa , etoposide , work different way stop tumor cell divide stop grow die . Combining chemotherapy autologous stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Isotretinoin may effective prevent recurrence glioma . It yet know regimen chemotherapy plus autologous stem cell transplantation without isotretinoin effective treat recurrent high-grade glioma . PURPOSE : This randomized phase III trial study high-dose chemotherapy intermediate-dose chemotherapy follow autologous stem cell transplantation see well work compare high-dose chemotherapy intermediate-dose chemotherapy follow autologous stem cell transplantation isotretinoin treat young patient recurrent high-grade glioma .</brief_summary>
	<brief_title>High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With Without Isotretinoin Treating Young Patients With Recurrent High-Grade Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival overall survival pediatric patient recurrent high-grade glioma treat single course high-dose carboplatin , etoposide , thiotepa autologous stem cell transplantation v multiple course intermediate-dose carboplatin thiotepa autologous stem cell transplantation without isotretinoin . - Compare number hospital day time engraftment patient treat regimen . - Compare toxic death rate patient treat regimen . - Compare tolerability isotretinoin patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord pathologic diagnosis ( glioblastoma multiforme v anaplastic astrocytoma v high-grade glioma ) . - Chemotherapy autologous stem cell reinfusion ( ASCR ) : Patients randomize 1 2 treatment arm . - Arm I ( high-dose chemotherapy ASCR ) : Patients receive high-dose chemotherapy comprise carboplatin IV 4 hour day -8 -6 ; thiotepa IV 3 hour etoposide IV 3 hour day -5 -3 ; filgrastim ( G-CSF ) IV subcutaneously ( SC ) daily begin day 1 continue blood count recover . Autologous peripheral blood stem cell ( PBSC ) bone marrow reinfused day 0 . - Arm II ( intermediate-dose chemotherapy ASCR ) : Patients receive intermediate-dose chemotherapy comprise carboplatin IV 4 hour thiotepa IV 3 hour day 1-2 G-CSF IV SC daily begin day 4 continue blood count recover . Autologous PBSC bone marrow reinfused day 3 . Treatment repeat every 28 day total 3 course . - Maintenance therapy : After recovery chemotherapy ( approximately day 30 post-transplantation ) , patient randomize 1 2 maintenance arm . - Arm I : Patients receive oral isotretinoin twice daily day 1-14 . Treatment repeat every 28 day total 6 course . - Arm II : Patients receive maintenance therapy . In arm , treatment continue absence disease progression . Patients follow every 3 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 80-150 patient ( 40-75 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 follow highgrade glioma : Glioblastoma multiforme Anaplastic astrocytoma Gliosarcoma Disease first relapse No primary brainstem spinal cord gliomas No secondary glioblastoma arise prior treatment nonglial tumor Prior local radiotherapy 5,0006,000 cGy require Less 1.5 cm residual gadoliniumenhancing tumor maximal crosssectional diameter MRI No metastatic tumor spinal MRI PATIENT CHARACTERISTICS : Age Under 21 diagnosis Performance status Lansky 50100 % OR Karnofsky 50100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 500/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Renal Glomerular filtration rate ≥ 60 mL/min AND/OR Creatinine clearance ≥ 60 mL/min Cardiovascular Shortening fraction ≥ 27 % echocardiogram OR Ejection fraction ≥ 50 % MUGA Pulmonary No dyspnea rest No exercise intolerance Pulse oximetry &gt; 94 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy No prior thiotepa No prior myeloablative chemotherapy Endocrine therapy No concurrent corticosteroid Radiotherapy See Disease Characteristics More 8 week since prior radiotherapy No prior craniospinal radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
</DOC>